Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | TPO | P07202 | 1/20 | 0.46 |
| ▸ | EPX | P11678 | 1/20 | 0.46 |
| ▸ | LPO | P22079 | 1/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.45 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564176 | 0.84 | LTA4H (0.60) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL4475083 | 0.82 | MAP4K4 (0.48) | CYP19A1MPOTPOEPXLPO | |
| SCHEMBL13895544 | 0.81 | CYP19A1 (0.59) | CYP19A1SCN9AKCNH2SCN5APARP15 | |
| SCHEMBL4371418 | 0.79 | MAP4K4 (0.49) | CYP19A1SCN9AKCNH2SCN5APARP15 | |
| SCHEMBL26013341 | 0.79 | ALDH1A1 (0.61) | PARP10LTA4HMPOTPOEPX | |
| SCHEMBL15584627 | 0.79 | CYP19A1 (0.56) | CYP19A1SCN9AKCNH2SCN5APARP15 | |
| SCHEMBL2707449 | 0.79 | CYP19A1 (0.56) | CYP19A1SCN9AKCNH2SCN5APARP15 | |
| SCHEMBL4376200 | 0.79 | CYP19A1 (0.60) | CYP19A1SCN9AKCNH2SCN5APARP15 | |
| SCHEMBL29729202 | 0.78 | — | — | |
| SCHEMBL221465 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| EP-1534276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1534276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1534276-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | CYP19A1 2152/4885SCN9A 343/4885KCNH2 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.